Dr. Tycel Phillips discusses the FDA approval of a Calquence combo in MCL, making it the first and only BTK inhibitor ...

Living with lymphoma for 15 years, I developed a concerning rash post-vacation, which led to a leukocytoclastic vasculitis ...

Researchers have published findings from the phase 2 LITESPARK-003 study of patients with previously untreated advanced clear ...

A study found no significant HRQOL differences between Erleada-based therapies and ADT plus AAP for advanced castration-sensitive prostate cancer.

A panelist discusses how polycythemia vera (PV) impacts daily life and lifestyle management, including beneficial changes ...

In resectable, locally advanced esophageal squamous cell carcinoma, neoadjuvant Tyvyt plus chemoradiotherapy led to an ...

One cancer vaccine may still be years away from being available, a breast cancer test may be misguiding treatments for Black ...

Dr. John Oertle discussed the significance of World Cancer Day, raising awareness about cancer care advancements and ...

Alecensa weight gain is underreported in ALK+ NSCLC trials, highlighting the need for increased awareness and proactive ...

Here is a select list of cancer therapies approved by the FDA throughout the month of January, featuring patient populations ...

Dr. Alan Tan spoke with CURE® about what patients with kidney cancer and providers who treat it may be able to learn from ...

Dr. Filippo Pietrantonio discusses OrigAMI-1 trial data which assessed Rybrevant in mutated, wild-type, non-HER2-amplified ...